Overview
Illumina Q3 revenue of $1.08 bln beats analyst expectations
Adjusted EPS of $1.34 for Q3 beats consensus estimates
Company repurchased 1.2 mln shares for $120 mln
Outlook
Company expects FY25 constant currency revenue decline of (1.5%) to (0.5%)
Illumina raises FY25 non-GAAP EPS guidance to $4.65 - $4.75
Company anticipates FY25 non-GAAP operating margin of 22.75% to 23%
Result Drivers
CLINICAL MARKET GROWTH - Revenue acceleration driven by growth in clinical market, Illumina's largest segment, per CEO Jacob Thaysen
EX-CHINA GROWTH - Company returned to growth outside of China, executing on strategic pillars for long-term targets
NEW TECHNOLOGIES - Launched 5-base solution and Constellation mapped read technology, enhancing genomic insights
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $1.08 bln | $1.07 bln (16 Analysts) |
Q3 Adjusted EPS | Beat | $1.34 | $1.16 (18 Analysts) |
Q3 EPS | $0.98 | ||
Q3 Adjusted Net Income | Beat | $206 mln | $181.62 mln (16 Analysts) |
Q3 Net Income | $150 mln | ||
Q3 Gross Margin | 67.6% | ||
Q3 Adjusted EBIT Margin | 24.5% | ||
Q3 Adjusted Gross Margin | 69.2% | ||
Q3 EBIT Margin | 21% |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 8 "strong buy" or "buy", 11 "hold" and 3 "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for Illumina Inc is $110.00, about 13.6% above its October 29 closing price of $95.03
Press Release: ID:nPn2khdXja
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)